Aktiechat - investeringstips

	9/11 17:08 af Jan Van de Winkel	We anticipate increased investment in our exciting product pipeline and we also are constantly scanning the landscape for potential opportunities for products or on the technology front
	9/11 17:07 af MrEbbe	Genmabs report states that it currently hold a position of 5 billion dkk in cash. Can we expect a dividend, or that the money can come out "work" instead of standing there? You have previously spoken about take over possibilities of competitors, is that possibility still on the table?
	9/11 17:05 af Jan Van de Winkel	No change in our guidance for 2017. We are confident in achieving our commitments and that Darzalex sales will be in our range of 1.1-1.3 bn USD.
	9/11 17:04 af Helge Larsen/PI-redaktør	Can you tell us about your guiding for the hole year?
	9/11 17:04 af Jan Van de Winkel	and exciting abstracts for upcoming ASH conference in December.
	9/11 17:04 af Jan Van de Winkel	and we announced a potential registrational trial for that product in cervical cancer in October.
	9/11 17:03 af Jan Van de Winkel	Important events: Alcyone interim data, Japan approval in RRMM, Seattle Genetics opting in for Tisotumab vedotin...
	9/11 17:02 af Jan Van de Winkel	and 296 mn DKK increase in Op income to 641 mn DKK. Cash position 5.2 bn DKK
	9/11 17:02 af Jan Van de Winkel	Of course, Q3 YTD revenue 1348 mn DKK up 52% year on year, expenses 707 Mn DKK up 30%....
	9/11 17:01 af Helge Larsen/PI-redaktør	Great. Can you give us a short-term update on key figures and important events in Q3?
	9/11 17:01 af Jan Van de Winkel	Looking forward to the questions....
	9/11 17:00 af Helge Larsen/PI-redaktør	Jan van de Winkel and David Eatwell. Welcome to Q & A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	9/11 16:58 af Jan Van de Winkel	Good afternoon, we are waiting to take your questions at 4pm CET
	9/11 16:58 af Helge Larsen/PI-redaktør	Jan and David. Are you online?